AstraZeneca’s Anti-IL-33 Antibody Tozorakimab Shows Progress in COPD Treatment
According to a recent publication in Nature Biotechnology on May 7, 2026, AstraZeneca’s investigational antibody, tozorakimab, is making significant strides in the treatment of Chronic Obstructive Pulmonary Disease (COPD). This newcomer anti-IL-33 therapy specifically targets interleukin-33, a key mediator involved in the disease's pathology. The article highlights that tozorakimab uniquely addresses two distinct signaling pathways central to COPD progression: inflammation and epithelial dysfunction. By inhibiting IL-33, the drug aims to reduce airway inflammation while simultaneously protecting the lung epithelium from damage, offering a dual-mechanism approach that differs from existing treatments. This development represents a notable advancement in respiratory medicine, potentially providing new hope for patients suffering from this chronic and debilitating condition. The report, authored by Charlotte Harrison, underscores the scientific community's growing interest in targeting specific inflammatory pathways to improve clinical outcomes in COPD management. As research continues, tozorakimab’s ability to modulate these critical biological processes positions it as a promising candidate in the evolving landscape of biologic therapies for respiratory diseases.
Wire timeline
AstraZeneca’s Anti-IL-33 Antibody Tozorakimab Shows Progress in COPD Treatment
According to a recent publication in Nature Biotechnology on May 7, 2026, AstraZeneca’s investigational antibody, tozorakimab, is making significant strides in the treatment of Chronic Obstructive Pulmonary Disease (COPD). This newcomer anti-IL-33 therapy specifically targets interleukin-33, a key mediator involved in the disease's pathology. The article highlights that tozorakimab uniquely addresses two distinct signaling pathways central to COPD progression: inflammation and epithelial dysfunction. By inhibiting IL-33, the drug aims to reduce airway inflammation while simultaneously protecting the lung epithelium from damage, offering a dual-mechanism approach that differs from existing treatments. This development represents a notable advancement in respiratory medicine, potentially providing new hope for patients suffering from this chronic and debilitating condition. The report, authored by Charlotte Harrison, underscores the scientific community's growing interest in targeting specific inflammatory pathways to improve clinical outcomes in COPD management. As research continues, tozorakimab’s ability to modulate these critical biological processes positions it as a promising candidate in the evolving landscape of biologic therapies for respiratory diseases.
Nature Biotechnology